Tempus AI, Inc. (TEM)
Quote, stock score, analyst consensus, and SEC filings, plus insider and Congress trades when there are any.
NasdaqGS · Price as of · Nasdaq Real Time Price
- Profitability8/20
Losing money, but both lines point the right way: the loss narrowed to $-189.3M over the last four reported quarters from $-245.0M the year before. Revenue over the last four reported quarters was $1.51B, up 37% from $1.11B the year before.
- Insider buying vs selling8/20
Insiders are sellers only: 102 sells worth $84.8M, no open-market buys, across the last 20 Form 4s. Routine executive selling is common, so this is only a mild negative.
- Dilution and offerings4/15
1 offering-related filing in the last year (share-count history unavailable).
- Analysts18
- Implied upside+11.7%
- Target range$70.00 to $120.00
TEM closed at $82.71 on Nov 10, up 21.7% since Oct 12. Chart read: price above both the 50-day and 200-day moving averages; the 50-day is above the 200-day (uptrend structure); trading at 95% of the 52-week range ($41.55 to $85.08).
Insider buying and selling at Tempus AI, Inc. (TEM)
The most recent Form 4 on record for Tempus AI, Inc. (TEM) is October 27, 2026, when Eric P Lefkofsky, CEO and Chairman, sold $17.6M of stock. That sale ran under a pre-arranged 10b5-1 plan, so it was scheduled ahead of time rather than decided that week.
| Insider | Action | Value | Date | Type |
|---|---|---|---|---|
| Eric P Lefkofsky · CEO and Chairman | Sell | $17.6M | October 27, 2026 | Routine |
| Eric P Lefkofsky · CEO and Chairman | Sell | $19.4M | September 22, 2026 | Routine |
| Eric P Lefkofsky · CEO and Chairman | Sell | $16.1M | September 17, 2026 | Routine |
| Eric P Lefkofsky · CEO and Chairman | Sell | $16.3M | August 25, 2026 | Routine |
| Eric P Lefkofsky · CEO and Chairman | Sell | $10.5M | July 28, 2026 | Routine |
Filed notices to sell
A Form 144 is filed beforean insider sells restricted stock. The Form 4 reporting the completed trade isn't due until two business days after the sale, so these land first. They are intentions, not transactions.
| Insider | Value | Filed | Status | Type |
|---|---|---|---|---|
| Fukushima Ryan · Officer | $5,778 | November 2, 2026 | Executed | Routine |
| LEFKOFSKY ERIC P · Officer, Director, 10% Stockholder | $16.8M | October 27, 2026 | Executed | Routine |
| Schoenherr Thomas Edward · Officer | $845,509 | September 25, 2026 | Executed | Routine |
| LEFKOFSKY ERIC P · Officer, Director, 10% Stockholder | $19.5M | September 22, 2026 | Executed | Routine |
| LEFKOFSKY ERIC P · Officer, Director, 10% Stockholder | $14.0M | September 17, 2026 | Executed | Routine |
SEC filings
| Form | Filed | Description |
|---|---|---|
| SCHEDULE 13G/A | November 6, 2026 | View on EDGAR |
| 4 | November 4, 2026 | View on EDGAR |
| 4 | November 4, 2026 | View on EDGAR |
| 144 | November 2, 2026 | View on EDGAR |
| 10-Q | November 2, 2026 | 10-Q |
| 8-K | November 2, 2026 | 8-K |
| 4 | October 29, 2026 | View on EDGAR |
| SCHEDULE 13G/A | October 28, 2026 | View on EDGAR |
Tempus AI news
Bristol Myers (BMY) leads Pathos AI's $237 million round; Tempus (TEM) to supply neurology data
Bristol Myers Squibb led the round and gets access to Pathos's AI platform for its drug research. Tempus will build a neurology dataset under a $55 million deal.
Tempus AI (TEM) rose 47% on a Merck and Moderna trial. Two analysts upgraded it after the run.
Cantor Fitzgerald initiated Tempus AI (TEM) at overweight with an $80 target, two days after Piper Sandler upgraded it. The 47% run both calls follow came from a Merck and Moderna Phase 3 readout, and the insider sales that made headlines were mostly automatic tax withholding.
Tempus AI (TEM) just turned its first profit. Its stock is still half off its high.
A deep dive on Tempus AI (TEM): what the cancer-data company does, its first quarterly profit, who controls the stock, the short-seller report against it, and why Wall Street can't agree on the price.
Frequently asked questions
What do analysts expect for TEM?
18 analysts cover Tempus AI, Inc. (TEM). The consensus rating is Buy. The average price target is $89.56, in a range of $70.00 to $120.00.
Are insiders buying or selling TEM?
We track Form 4 filings for Tempus AI, Inc. (TEM). The activity listed on this page shows 5 qualifying sales. Each row is labelled Routine when the filer declared a pre-arranged 10b5-1 plan, Tax withholding when shares were sold automatically to cover the tax on a vest, or Own call when neither applies.
Where can I see TEM SEC filings?
Recent filings are listed on this page, newest first. The latest is a SCHEDULE 13G/A filed November 6, 2026.